Duane Morris

Overview

Duane Morris is a global law firm with life-sciences, healthcare, pharmacy, and intellectual-property practices serving pharmaceutical, biotech, medical-device, pharmacy, PBM, provider, and health-system clients. For a manufacturer buyer, the relevant lane is legal counsel: FDA / DEA regulatory advice, IP strategy, Hatch-Waxman / BPCIA disputes, pharmacy and PBM regulation, healthcare enforcement, product liability, clinical-trial contracting, and life-sciences transactions.

It should not be evaluated like an operational regulatory vendor. Duane Morris does not belong in the same comparison set as pharmacovigilance case-processing vendors, safety databases, prior-authorization workflow platforms, hub operators, or reimbursement processors. Use the profile when the launch or commercialization risk is legal, contractual, regulatory, or litigation-sensitive.

Regulatory Compliance Capability Model

The framework below standardizes how Rx Almanac evaluates regulatory-compliance capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Duane Morris is evaluated as an advisory and litigation partner, not a managed-service operations vendor.

Capability	Buyer should compare	Duane Morris readout
Regulatory strategy and submissions	Submission planning, agency interactions, labeling strategy, variations, lifecycle management, and global filing support.	Core regulatory support. Duane Morris markets life-sciences and healthcare regulatory counsel across pharmaceuticals, biologics, medical devices, diagnostics, regenerative medicine, gene editing, and related technologies.
Pharmacovigilance and safety operations	ICSR intake, case processing, signal detection, aggregate reports, REMS/safety support, and safety databases.	Not the use case. Treat these as out of scope unless Duane Morris is advising on legal risk around another vendor’s operations.
Quality systems and compliance auditing	GxP quality systems, SOPs, audits, inspection readiness, CAPA, vendor oversight, and training.	Documented, validate scope. The firm has healthcare litigation and enforcement capabilities, but buyers should confirm the exact team, jurisdiction, and matter analogs.
Labeling, promotional review, and medical/legal support	Label operations, MLR review, promotional compliance, medical information, and claims substantiation.	Documented, validate workflow. Duane Morris fits as legal counsel for review and dispute risk; manufacturers still need internal or agency-side MLR operations.
Licensing, accreditation, and specialized counsel	Pharmacy, PBM, state licensing, accreditation, healthcare law, and niche regulatory counsel.	Core life-sciences IP work. The firm highlights life-sciences IP, patent prosecution, patent litigation, ANDA-related litigation, and LMG Life Sciences recognition in patent prosecution. Core PA casework. Duane Morris publishes on PBM reform, pharmacy-ownership litigation, and pharmacy industry legal scrutiny; this is legal advisory, not claims or PA operations. Core access strategy. Public materials include the Veraxa Biotech SPAC merger representation and life-sciences corporate / licensing recognition.
Technology, workflow, and reporting infrastructure	Validated systems, regulatory information management, safety platforms, dashboards, and workflow automation.	Not the main buying reason for Duane Morris; validate only if the SOW includes technology, workflow, and reporting infrastructure.

Buyer Fit

• Include when: Include Duane Morris when the work requires legal interpretation, defense, negotiation, regulatory advice, or litigation strategy across life sciences, healthcare, pharmacy, PBM, or FDA-regulated products.
• Strongest use cases: FDA / DEA questions, patent strategy, Hatch-Waxman / BPCIA litigation, pharmacy / PBM reform, 340B or reimbursement disputes, False Claims Act risk, clinical-trial contracting, licensing, M&A, and commercialization agreements.
• Market access fit: Use as legal counsel for PBM, pharmacy, reimbursement, formulary, 340B, contracting, and state/federal reform issues; pair with market-access consultants when the work requires payer research, GTN modeling, value messaging, or access strategy execution.
• Not a fit for: PV case processing, safety operations, prior authorization automation, hub services, benefits verification, copay operations, or regulatory information management software.
• Commercial fit: Pricing is custom / matter-based. Buyers should scope partner involvement, associate leverage, jurisdiction coverage, response timelines, conflicts, and whether the engagement requires local counsel or a separate operational vendor.

Differentiators

• Life-sciences IP bench: Duane Morris is publicly recognized by LMG Life Sciences for patent prosecution, with named life-sciences lawyers across patent prosecution, strategy, litigation, Hatch-Waxman, corporate, licensing, collaboration, M&A, venture capital, and product liability.
• Pharmacy / PBM law signal: The firm publishes current analysis on PBM reform, pharmacy ownership restrictions, pharmacy hubs, reimbursement scrutiny, and related litigation.
• Transaction capability: The Veraxa Biotech SPAC merger representation gives a recent public life-sciences transaction signal.
• Large-firm coverage: The firm can cover legal issues that cut across healthcare, IP, corporate, litigation, employment, privacy, and regulated-products work.

RFP Questions

• Which partner will be accountable for the matter, and what similar pharma / biotech / pharmacy matters have they handled?
• How does the team have the right mix of FDA / DEA, IP, pharmacy, PBM, healthcare enforcement, and transaction experience for the specific issue?
• How will Duane Morris coordinate with internal counsel, market-access consultants, agencies, hub vendors, or operational compliance vendors?
• What work is legal advice versus operational execution that must be handled by another vendor?
• What conflicts, state-law limits, local-counsel needs, or privilege considerations should be resolved before engagement?
• How will budget, staffing leverage, timelines, escalation, and deliverable ownership be controlled?

Recent Activity

• March 2026: Published on West Virginia PBM compliance penalties and heightened state scrutiny of PBM reimbursement, rebate, pharmacy, and health-plan relationships.
• January 2026: Published on congressional PBM reform, pharmacy hubs, and contract standards affecting any-willing-pharmacy requirements.
• September 2025: Recognized by LMG Life Sciences for patent prosecution; five partners named Life Sciences Stars.
• August 2025: Published on the preliminary injunction against Arkansas’ PBM pharmacy-ownership ban.
• April 2025: Represented Veraxa Biotech AG in a $1.3B SPAC merger agreement with Voyager Acquisition Corp.